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Chronic Lymphoproliferative Disorders
A pilot study of low-dose subcutaneous
alemtuzumab therapy for patients with
hemotherapy-refractory chronic lymphocytic
leukemia
Subcutaneous low-dose alemtuzumab (10 mg t.i.w.
for 18 weeks) induced a 50% response rate, including
25% complete response, in 16 patients with refracto-
ry chronic lymphocytic leukemia (CLL) patients. The
responses were substantial even in patients with
unfavorable cytogenetics, fludarabine/rituximab
refractoriness, Rai stage IV, previous infections, and
age over 65 years. Subcutaneous low-dose alem-
tuzumab is effective in poor prognosis B-CLL, and has
a particularly favourable toxicity profile.haematologica 2005; 90:410-412
(http://www.haematologica.org/journal/2005/03/410.html)
Patients with chronic lymphocytic leukemia (CLL) who
are resistant/refractory to alkylating agents and/or flu-
darabine1-3 have a poor prognosis, with a median survival
duration of only 10 months.4
In this subset of high-risk patients, alemtuzumab has
been shown to induce a significant overall response rate
of 33%.2 However, treatment with alemtuzumab accord-
ing to the conventional administration schedule (30 mg
three times a week intravenously) is associated with a
consistent number of reactions and significant infectious
morbidity.5,6 It has recently been reported that both the
percentage and severity of first dose reactions can be dra-
matically reduced by the subcutaneous administration of
alemtuzumab 30 mg three times weekly for 18 weeks.7
On the basis of these data we decided to assess the effi-
cacy and safety of prolonged treatment with subcuta-
neous low-dose alemtuzumab (10 mg three times a week
for 18 weeks) in a cohort of 16 heavily pre-treated B-CLL
patients. 
Sixteen patients were enrolled. The patients had
received a median of three prior lines of therapy, all were
refractory to alkylating agents, fourteen were refractory
to fludarabine, and two were not allowed a purine ana-
log-containing therapy due to previous Coombs’-positive
anemia. Half of the patients were also refractory to ritux-
imab-containing regimens. Half of the patients had had
infections during the six months preceding the start of
alemtuzumab therapy. Two patients with hepatitis B
virus (HBV) reactivation were on lamivudine therapy,
which was continued during treatment with alemtuzum-
ab (Table 1).
All patients received at least four weeks of alemtuzum-
ab therapy; twelve patients completed all 18 weeks of
treatment. The reasons for treatment withdrawal during
weeks 4-14 were the achievement of a complete
response (3 patients), and infection (1 patient). 
The overall response, according to NCIWG criteria,8 of
the patients enrolled in this pilot study was 50%, includ-
ing 25% complete responses. No progressive disease was
observed during treatment. An objective response was
documented in 50% of the patients refractory to both
alkylators and fludarabine. Three of the eight patients
resistant to rituximab responded to alemtuzumab. Overall
response was 43.3% in the patients with an abnormal
karyotype and 37.5% in patients with unfavorable cyto-
genetic alterations. The two patients with p53 gene dele-
tions [del(17)(p13.1)] both showed a partial response after
alemtuzumab therapy. The therapy was exceptionally
well tolerated by the older patients, with remarkable
responses in terms of percentage and quality (Table 2). A
higher proportion of patients achieved responses in blood
(93.7%) and bone marrow (62.5%), as compared with
lymph nodes and spleen (50% and 42.9%, respectively).
The time to achieve a 1-log depletion of peripheral blood
lymphocytes (PBL) was more rapid in responders than in
non-responders (3 weeks versus 8 weeks), and was partic-
ularly quick in complete responders (2.5 weeks). This
observation, simply made by assessing PBL counts using a
hematologic analyzer, is in line with the results of the ele-
gant study by Rawstron et al.9
Four patients died of progressive disease or infectious
complications after a median follow-up of nine months,
all of whom were non-responders. The median survival
of our non-responding patients is therefore comparable
with that observed in CLL patients failing purine analog
therapy. In contrast, the patients who achieve a response
after low-dose alemtuzumab are all alive after a median
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follow-up of 12.5 months, with non-progressive disease
in seven of the eight patients.
In terms of efficacy, our results are therefore compara-
ble to those obtained using i.v. alemtuzumab, but with
less toxicity. In fact, no infusion-related effect was
observed except for a mild local reaction at the site of
injection in about half of the patients, and transient low-
grade fever in a quarter of them. Overall, five patients
had suspected or proven infective complications and one
died because of polymicrobial infection. No CMV infec-
tion was observed, but only transient and asymptomatic
reactivation in two patients, which subsided without any
specific treatment. Our patients were all treated with cot-
rimoxazole, and no PCP was observed. The association
of alemtuzumab with reverse transcriptase inhibitors was
well tolerated and effectively inhibited HBV proliferation
in two patients with active HBV infection. We therefore
confirm the observation by Heider et al. on lamivudine
efficacy in a patient on alemtuzumab therapy.10 Fur-
thermore, we show that the addition of adefovir is able
to completely abrogate HBV viral flare-up in a patient
resistant to lamivudine. Most of our patients experienced
transient cytopenias, which were generally reversible.
Only three of the patients received granulocyte colony-
stimulating factor (CSF) (a median of sixteen doses).
Alemtuzumab was safely administered to patients with a
history of autoimmune hemolytic anemia (AIHA). In fact,
only one patient showed reactivation of hemolysis six
weeks after the end of antibody therapy, whereas no
signs of active hemolysis could be detected in the other
three who had had AIHA. 
This regimen seems to be as effective as standard intra-
venous infusion and has a particularly favorable toxicity
profile. It may therefore represent a more convenient
approach for patients and physicians by allowing home
administration and reducing health care costs. Further
studies and a longer follow-up are necessary to validate
our results.
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Table 1. Patients’ characteristics (n=16). 
Characteristic Patients 
Age, y (median, range) 67 (48-83)
Binet stage, %
A 0
B 56.2
C 43.8
Cytogenetic %
Abnormal 56.2
>2 abn. 18.8
13q- (single) 6.2
+12 12.5
11q- 18.8
17p- 12.5
Previous infections % 50.0
Pseudomonas pneumonia 6.2
Pseudomonas otitis 6.2
HBV reactivation 12.5
CMV reactivation 6.2
Mycobacterium chel. disseminated cutaneous infection 6.2
VZV 12.5
Previous chemotherapy % 100.0
Failed alkylating agents 100.0
Failed fludarabine 87.5*
Failed rituximab 50.0
AIHA 25.0°
*Fludarabine was not allowed in two patients with AIHA; °previous therapy with
fludarabine in two out of four AIHA patients. 
Table 2. Response (%) to low-dose subcutaneous alemtuzumab in
16 refractory B-CLL patients
Group OR CR PR SD PD
All patients (n=16) 50.0 25.0 25.0 50.0 0
Failed fludarabine (n=14*) 50.0 21.4 28.6 42.9 0
Failed rituximab (n=8) 37.5 25.0 12.5 63.5 0
Stage IV C (n=7) 42.9 14.3 28.6 57.1 0
Previous infection (n=8) 50.0 25.0 25.0 50.0 0
Unfavorable cytogenetic (n=8) 37.5 12.5 25.0 62.5 0
Age < 70 years  (n=11) 54.6 18.2 36.4 45.4 0≥70          (n=5) 60 40 20 40 0
*Fludarabine was not allowed in two patients with active AIHA; OR, overall
response; CR, complete response; PR, partial response; SD, stable disease; PD, pro-
gressive disease.
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Acute Myeloid Leukemia
Low frequency of exon 3 PTPN11 mutations in
adult de novo acute myeloid leukemia. Analysis
of a consecutive series of 173 patients
A total of 173 samples obtained from adult
patients with de novo acute myeloid leukemia
(AML) were assayed for exon 3 PTPN11 mutations
by single strand conformation polymorphism
(SSCP) analysis and direct sequencing. Only three
monocytic leukemias had point mutations (1.73%).
haematologica 2005; 90:412-413
(http://www.haematologica.org/journal/2005/03/412.html)
The PTPN11 gene encodes the non-receptor-type pro-
tein tyrosine phosphatase SHP-2 (src homology region 2-
domain phosphatase-2) which plays an important role in
the response to extracellular stimuli and is required for
the activation of the RAS/MEK/ERK kinase pathway.
PTPN11 has been identified as the gene causing Noonan
syndrome and it has also been found to be mutated in
34% of cases of juvenile myelomonocytic leukemia.1,2
Reported acquired mutations in myeloid malignancies
cause a gain-of-function of the SHP-2 protein.3,4
To assess the relevance of acquired PTPN11 mutations
in de novo adult AML we performed a mutational analy-
sis in a consecutive series of 173 patients enrolled in the
Spanish CETLAM protocol. DNA obtained from the
diagnostic bone marrow was purified by digestion with
proteinase K, extraction by the salting out method, and
precipitation with ethanol. The configuration of the MLL
locus was analyzed by hybridizing BamHI- and Hind III-
digested DNA to the B859 probe. AML1-ETO and CBF‚-
MYH11 transcripts were assayed by reverse transcription
polymerase chain reaction (RT-PCR) methods. The FLT-3
tandem duplication of the JM domain was investigated
by genomic PCR. The D835 mutation was ruled out by
means of DNA-PCR followed by EcoRV enzyme diges-
tion. Detection of exon 3 PTPN11 gene mutations was
studied by means of radioactive SSCP. The primers and
PCR protocols have been published elsewhere.1,2 Direct
sequencing was performed using forward and reverse
primers in these cases with abnormal conformers on
SSCP analysis using the ABI Prism dRhodamine Term-
inator Cycle Sequence Ready Reaction kit (PE Bio-
systems, Warrington, UK) and the ABI PRISM 310
Genetic Analyzer (Foster City, CA, USA).
We detected three M5 AML cases harboring point
mutations (Table 1), representing a prevalence of 1.73%.
These findings are in line with those reported by Johan et
al.5 in 64 AML cases enrolled in the MRC trials and sug-
gest that this molecular lesion is rare in de novo adult
AML, and clearly  less common than in AML in children.
Interestingly, most pediatric cases corresponded to
monocytic leukemias. Mutations at codon 60 and 72,
located at interaction sites between the N-SH2 and PTP
domains, have been previously reported whereas the
mutation at codon 53 has not been described to date.
One of the cases reported here showed a +8, another a
–7, and the remaining case had a normal karyotype. We
were not able to detect the associated FLT3 or MLL
rearrangements commonly encountered in monocytic
leukemias. All three patients died within a relatively
short period: patient #1 from infectious complications
arising in the context of graft-versus-host disease, patient
#2 from severe bleeding in the induction phase and
patient #3 relapsed. It can be concluded that PTPN11
mutations affect a low percentage of patients with de
novo AML and appear to be restricted to cases with a
monocytic differentiation.
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Table 1. PTPN11 mutated AML cases.
Pt. Sex Age Dx WBC Cytogenetics FLT3, MLL PTPN11 Outcome
1 M 59 M5 73¥109/L 45,XY,-7 GL G60V Dead 5m
2 F 48 M5 145¥109/L 46,XX GL A72V Dead 1m
3 M 35 M5 19¥109/L 47,XY,+8 GL H53Q Dead 3m
M: male F: female; Dx: diagnosis according to FAB classification; GL: germ line.
